CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TherVacB is focused on developing a therapeutic vaccine for chronic hepatitis B infection. By enhancing immune responses through a prime-boost vaccination strategy, it aims to achieve a cure and improve patient outcomes, particularly in regions with high HBV prevalence.
Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium.
They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure.
TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure.
Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous r…
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
